Retrospective analysis of inotuzumab-associated hepatotoxicity in adult patients with B-cell acute lymphoblastic leukemia: Expanding the Spectrum of calicheamicin syndrome
/l; p = 0.03), while ALP elevations were similar between groups. Median time to hepatotoxicity improvement after InO discontinuation was 18 days, and no patients progressed to SOS.ConclusionCalicheamicin Syndrome represents a reproducible and reversible hepatotoxic entity distinct from SOS, characterized by InO exposure, transaminitis, thrombocytopenia, abnormal hepatic imaging, and HSC on pathology. Early recognition may facilitate monitoring and prevent progression to severe hepatic injury.
Authors
- Kareem Latif (ORCID: https://orcid.org/0000-0002-2417-7981)
- Jasmine Cha
- Priscilla Soria
- Kum‐Ja Lee
- Derek Tai (ORCID: https://orcid.org/0000-0002-6461-5560)
- Pranati Shah (ORCID: https://orcid.org/0009-0003-0331-892X)
- Mojtaba Akhtari
- Nidhi Kejriwal
- Daniel Park
- Karina Basmajian
Institutions
- University of California, Riverside (US)
- University of Southern California (US)
- Loma Linda University Medical Center (US)
- Loma Linda University (US)
- Arrowhead Regional Medical Center (US)
- California Southern University (US)
- Harbor–UCLA Medical Center (US)
Publication Details
- Journal
- Journal of Oncology Pharmacy Practice
- Published
- 2026-04-10
- DOI
- https://doi.org/10.1177/10781552261441537
- Primary Topic
- Acute Lymphoblastic Leukemia research
- Type
- article
- Field-Weighted Citation Impact
- 0.00